Akihiro Inazu

List of Publications by Year in Descending Order

134 papers	4,873 citations	37 h-index	66 g-index
146 ext. papers	5,268 ext. citations	5.1 avg, IF	4.65 L-index

#	Paper	IF	Citations
134	A teenager boy with a novel variant of Sitosterolemia presented with pancytopenia.. *Clinica Chimica Acta*, **2022**,	6.2	0
133	Prevalence, self-awareness, and LDL cholesterol levels among patients highly suspected as familial hypercholesterolemia in a Japanese community. *Practical Laboratory Medicine*, **2020**, 22, e00181	1.7	2
132	Serum sitosterol level predicting ABCG5 or ABCG8 genetic mutations. *Clinica Chimica Acta*, **2020**, 507, 11-16	6.2	4
131	Hokuriku-plus familial hypercholesterolaemia registry study: rationale and study design. *BMJ Open*, **2020**, 10, e038623	3	3
130	Remnant lipoproteins and atherosclerotic cardiovascular disease. *Clinica Chimica Acta*, **2019**, 490, 1-5	6.2	9
129	Clinical whole exome sequencing in severe hypertriglyceridemia. *Clinica Chimica Acta*, **2019**, 488, 31-39	6.2	4
128	Remnant-like particles and coronary artery disease in familial hypercholesterolemia. *Clinica Chimica Acta*, **2018**, 482, 120-123	6.2	11
127	Assessment of arterial stiffness in patients with familial hypercholesterolemia. *Journal of Clinical Lipidology*, **2018**, 12, 397-402.e2	4.9	14
126	Sitosterolemia, Hypercholesterolemia, and Coronary Artery Disease. *Journal of Atherosclerosis and Thrombosis*, **2018**, 25, 783-789	4	55
125	Post-prandial Remnant Lipoprotein Metabolism in Sitosterolemia. *Journal of Atherosclerosis and Thrombosis*, **2018**, 25, 1188-1195	4	6
124	Molecular and functional characterization of familial chylomicronemia syndrome. *Atherosclerosis*, **2018**, 269, 272-278	3.1	8
123	HDL(3) Cholesterol Levels in an Elderly Population. *Journal of Atherosclerosis and Thrombosis*, **2018**, 25, 40-41	4	2
122	Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease. *Journal of Clinical Lipidology*, **2018**, 12, 1436-1444	4.9	46
121	Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. *Circulation Research*, **2017**, 121, 81-88	15.7	48
120	Assessments of Carotid Artery Plaque Burden in Patients With Familial Hypercholesterolemia. *American Journal of Cardiology*, **2017**, 120, 1955-1960	3	17
119	Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis. *Atherosclerosis*, **2017**, 265, 225-230	3.1	16
118	Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. *European Heart Journal*, **2017**, 38, 1573-1579	9.5	78

117	Lipid Management in a Japanese Community:Attainment Rate of Target Set by the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2012. *Journal of Atherosclerosis and Thrombosis*, **2017**, 24, 338-345	4	23
116	CETP Deficiency and Concerns in CETP Inhibitor Development **2017**, 23-35		0
115	Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations. *Circulation Journal*, **2016**, 80, 512-8	2.9	51
114	Prevalence, clinical features, and prognosis of patients with extremely low high-density lipoprotein cholesterol. *Journal of Clinical Lipidology*, **2016**, 10, 1311-1317	4.9	7
113	Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy. *Lipids in Health and Disease*, **2016**, 15, 66	4.4	5
112	A de novo mutation of the LDL receptor gene as the cause of familial hypercholesterolemia identified using whole exome sequencing. *Clinica Chimica Acta*, **2016**, 453, 194-6	6.2	8
111	A Rare Coincidence of Sitosterolemia and Familial Mediterranean Fever Identified by Whole Exome Sequencing. *Journal of Atherosclerosis and Thrombosis*, **2016**, 23, 884-90	4	14
110	Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography. *American Journal of Cardiology*, **2015**, 115, 724-9	3	46
109	Clinical characteristics of Japanese patients with severe hypertriglyceridemia. *Journal of Clinical Lipidology*, **2015**, 9, 519-24	4.9	25
108	Whole exome sequencing combined with integrated variant annotation prediction identifies asymptomatic Tangier disease with compound heterozygous mutations in ABCA1 gene. *Atherosclerosis*, **2015**, 240, 324-9	3.1	14
107	Extreme Contrast of Postprandial Remnant-Like Particles Formed in Abetalipoproteinemia and Homozygous Familial Hypobetalipoproteinemia. *JIMD Reports*, **2015**, 22, 85-94	1.9	10
106	Lipoprotein metabolism in familial hypercholesterolemia: Serial assessment using a one-step ultracentrifugation method. *Practical Laboratory Medicine*, **2015**, 1, 22-27	1.7	2
105	Autosomal recessive hypercholesterolemia: a mild phenotype of familial hypercholesterolemia: insight from the kinetic study using stable isotope and animal studies. *Journal of Atherosclerosis and Thrombosis*, **2015**, 22, 1-9	4	20
104	Infantile Cases of Sitosterolaemia with Novel Mutations in the ABCG5 Gene: Extreme Hypercholesterolaemia is Exacerbated by Breastfeeding. *JIMD Reports*, **2015**, 21, 115-22	1.9	42
103	Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation. *Atherosclerosis*, **2014**, 236, 54-61	3.1	60
102	Clinical significance of measuring soluble LR11, a circulating marker of atherosclerosis and HbA1c in familial hypercholesterolemia. *Clinical Biochemistry*, **2014**, 47, 1326-8	3.5	9
101	Marked transient hypercholesterolemia caused by low-dose mitotane as adjuvant chemotherapy for adrenocortical carcinoma. *Journal of Atherosclerosis and Thrombosis*, **2014**, 21, 1326-9	4	3
100	Cholesteryl Ester Transfer Protein Inhibitors **2014**, 195-220		1

99	Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors. *Molecules and Cells*, **2014**, 37, 777-84	3.5	37
98	Post-prandial remnant lipoprotein metabolism in autosomal recessive hypercholesterolaemia. *European Journal of Clinical Investigation*, **2012**, 42, 1094-9	4.6	16
97	Novel mutations of cholesteryl ester transfer protein (CETP) gene in Japanese hyperalphalipoproteinemic subjects. *Clinica Chimica Acta*, **2012**, 413, 537-43	6.2	13
96	Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia. *American Journal of Cardiology*, **2012**, 109, 364-9	3	31
95	Altered metabolism of low-density lipoprotein and very-low-density lipoprotein remnant in autosomal recessive hypercholesterolemia: results from stable isotope kinetic study in vivo. *Circulation: Cardiovascular Genetics*, **2012**, 5, 35-41		40
94	Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study. *Clinica Chimica Acta*, **2011**, 412, 1068-75	6.2	10
93	Postprandial lipoprotein metabolism: VLDL vs chylomicrons. *Clinica Chimica Acta*, **2011**, 412, 1306-18	6.2	88
92	Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan. *Atherosclerosis*, **2011**, 214, 404-7	3.1	82
91	Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study. *Atherosclerosis*, **2011**, 217, 165-70	3.1	35
90	A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene. *Atherosclerosis*, **2011**, 219, 663-6	3.1	36
89	Impacts of visceral adipose tissue and subcutaneous adipose tissue on metabolic risk factors in middle-aged Japanese. *Obesity*, **2010**, 18, 153-60	8	61
88	Plasma Cholesteryl Ester Transfer Protein (CETP) in Relation to Human Pathophysiology **2010**, 35-59		1
87	The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. *Atherosclerosis*, **2010**, 210, 166-72	3.1	50
86	Identification of a novel missense mutation in the sterol 27-hydroxylase gene in two Japanese patients with cerebrotendinous xanthomatosis. *Internal Medicine*, **2010**, 49, 1127-31	1.1	14
85	Hypolipidemic effect of Pleurotus eryngii extract in fat-loaded mice. *Journal of Nutritional Science and Vitaminology*, **2010**, 56, 48-53	1.1	26
84	Contribution of visceral adiposity and insulin resistance to metabolic risk factors in Japanese men. *Metabolism: Clinical and Experimental*, **2010**, 59, 748-54	12.7	12
83	Human Cholesteryl Ester Transfer Protein in Human HDL Metabolism **2010**, 95-101		
82	A deficiency of cholesteryl ester transfer protein whose serum remnant-like particle-triglyceride significantly increased, but serum remnant-like particle-cholesterol did not after an oral fat load. *Annals of Clinical Biochemistry*, **2009**, 46, 457-63	2.2	10

81	Comparison of waist circumference with body mass index for predicting abdominal adipose tissue. *Diabetes Research and Clinical Practice*, **2009**, 83, 100-5	7.4	54
80	Apolipoprotein B gene mutations and fatty liver in Japanese hypobetalipoproteinemia. *Clinica Chimica Acta*, **2009**, 399, 64-8	6.2	14
79	A novel method for determining functional LDL receptor activity in familial hypercholesterolemia: application of the CD3/CD28 assay in lymphocytes. *Clinica Chimica Acta*, **2009**, 400, 42-7	6.2	18
78	Cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells to serum is preserved in CETP-deficient patients. *Clinica Chimica Acta*, **2009**, 402, 19-24	6.2	25
77	Formation of prebeta1-HDL during lipolysis of triglyceride-rich lipoprotein. *Biochemical and Biophysical Research Communications*, **2009**, 379, 55-9	3.4	23
76	Marked aortic valve stenosis progression after receiving long-term aggressive cholesterol-lowering therapy using low-density lipoprotein apheresis in a patient with familial hypercholesterolemia. *Circulation Journal*, **2009**, 73, 963-6	2.9	103
75	Difference between fasting and nonfasting triglyceridemia; the influence of waist circumference. *Journal of Atherosclerosis and Thrombosis*, **2009**, 16, 633-40	4	13
74	Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. *Clinical Pharmacology and Therapeutics*, **2008**, 83, 731-9	6.1	29
73	Postprandial triglyceridaemia in men with impaired fasting glucose, impaired glucose tolerance and diabetes. *Diabetic Medicine*, **2008**, 25, 1008-10	3.5	5
72	Decreased post-prandial triglyceride response and diminished remnant lipoprotein formation in cholesteryl ester transfer protein (CETP) deficiency. *Atherosclerosis*, **2008**, 196, 953-7	3.1	37
71	A novel method for measuring human lipoprotein lipase and hepatic lipase activities in postheparin plasma. *Journal of Lipid Research*, **2008**, 49, 1431-7	6.3	26
70	Abstract 1921: Clinical Impact of Heterozygous Carrier of Autosomal Recessive Hypercholesterolemia on Asymptomatic Hyperlipidemic Patients: Evidence From Familial Gene Analysis. *Circulation*, **2008**, 118,	16.7	1
69	A novel method for measuring human hepatic lipase activity in postheparin plasma. *Journal of Lipid Research*, **2007**, 48, 453-7	6.3	10
68	The relationship of serum lipoprotein lipase mass with fasting serum apolipoprotein B-48 and remnant-like particle triglycerides in type 2 diabetic patients. *Hormone and Metabolic Research*, **2007**, 39, 612-6	3.1	8
67	Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect. *Current Drug Therapy*, **2007**, 2, 39-51	0.7	2
66	High frequency of a retinoid X receptor gamma gene variant in familial combined hyperlipidemia that associates with atherogenic dyslipidemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 923-8	9.4	22
65	Serum lipoprotein lipase mass: clinical significance of its measurement. *Clinica Chimica Acta*, **2007**, 378, 7-12	6.2	33
64	Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. *Atherosclerosis*, **2007**, 195, e182-9	3.1	76

63	Effects of fenofibrate therapy on plasma ubiquinol-10 and ubiquinone-10 levels in Japanese patients with hyperlipidemia and type 2 diabetes mellitus. *Pharmacotherapy*, **2006**, 26, 447-51	5.8	5
62	The relationship of percent body fat by bioelectrical impedance analysis with blood pressure, and glucose and lipid parameters. *Journal of Atherosclerosis and Thrombosis*, **2006**, 13, 221-6	4	19
61	Cholesterol-years score is associated with development of senile degenerative aortic stenosis in heterozygous familial hypercholesterolemia. *Journal of Atherosclerosis and Thrombosis*, **2006**, 13, 323-8	4	10
60	Effect of walking with a pedometer on serum lipid and adiponectin levels in Japanese middle-aged men. *Journal of Atherosclerosis and Thrombosis*, **2006**, 13, 197-201	4	29
59	CETP (cholesteryl ester transfer protein) promoter -1337 C>T polymorphism protects against coronary atherosclerosis in Japanese patients with heterozygous familial hypercholesterolaemia. *Clinical Science*, **2006**, 111, 325-31	6.5	17
58	Cholesteryl ester transfer protein inhibitors: new strategies for raising high-density lipoprotein cholesterol. *Future Lipidology*, **2006**, 1, 487-500		3
57	ATP-binding cassette transporter G8 M429V polymorphism as a novel genetic marker of higher cholesterol absorption in hypercholesterolaemic Japanese subjects. *Clinical Science*, **2005**, 109, 183-8	6.5	41
56	Efficacy of colestimide coadministered with atorvastatin in japanese patients with heterozygous familial hypercholesterolemia (FH). *Circulation Journal*, **2005**, 69, 515-20	2.9	14
55	Type III hyperlipoproteinemia exaggerated by Sheehan's syndrome with advanced systemic atherosclerosis: a 28-year clinical course. *Circulation Journal*, **2005**, 69, 746-51	2.9	7
54	Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. *Journal of Atherosclerosis and Thrombosis*, **2005**, 12, 111-9	4	96
53	Relationship of lipoprotein lipase and hepatic triacylglycerol lipase activity to serum adiponectin levels in Japanese hyperlipidemic men. *Hormone and Metabolic Research*, **2005**, 37, 505-9	3.1	34
52	Long-term course of lipoprotein lipase (LPL) deficiency due to homozygous LPL(Arita) in a patient with recurrent pancreatitis, retained glucose tolerance, and atherosclerosis. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 6541-4	5.6	35
51	Cutoff point separating affected and unaffected familial hypercholesterolemic patients validated by LDL-receptor gene mutants. *Journal of Atherosclerosis and Thrombosis*, **2005**, 12, 35-40	4	14
50	Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. *Journal of Lipid Research*, **2004**, 45, 448-55	6.3	81
49	Detailed analysis of serum lipids and lipoproteins from Japanese type III hyperlipoproteinemia with apolipoprotein E2/2 phenotype. *Clinica Chimica Acta*, **2004**, 348, 35-40	6.2	12
48	Identification of two novel missense mutations (p.R1221C and p.R1357W) in the ABCC6 (MRP6) gene in a Japanese patient with pseudoxanthoma elasticum (PXE). *Internal Medicine*, **2004**, 43, 1171-6	1.1	22
47	Difference in the risk factors for coronary, renal and other peripheral arteriosclerosis in heterozygous familial hypercholesterolemia. *Circulation Journal*, **2004**, 68, 623-7	2.9	20
46	Dual effects on HDL metabolism by cholesteryl ester transfer protein inhibition in HepG2 cells. *American Journal of Physiology - Endocrinology and Metabolism*, **2003**, 284, E1210-9	6	13

45	Haplotype analyses of cholesteryl ester transfer protein gene promoter: a clue to an unsolved mystery of TaqIB polymorphism. *Journal of Molecular Medicine*, **2003**, 81, 246-55	5.5	41
44	Therapeutic implications of cholesteryl ester transfer protein inhibitors in hyperlipidemia and low high-density lipoprotein-cholesterolemia. *Current Opinion in Investigational Drugs*, **2003**, 4, 291-7		5
43	Double deletions and missense mutations in the first nucleotide-binding fold of the ATP-binding cassette transporter A1 (ABCA1) gene in Japanese patients with Tangier disease. *Journal of Human Genetics*, **2002**, 47, 325-9	4.3	20
42	Carotid artery intima-media thickness and brachial artery flow-mediated vasodilation in asymptomatic Japanese male subjects amongst apolipoprotein E phenotypes. *Journal of Internal Medicine*, **2002**, 252, 114-20	10.8	31
41	Association of estrogen receptor-alpha gene polymorphisms with coronary artery disease in patients with familial hypercholesterolemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2002** , 22, 817-23	9.4	89
40	Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. *Clinical Science*, **2002**, 103, 587-94	6.5	97
39	Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. *Atherosclerosis*, **2002**, 163, 157-64	3.1	66
38	Effects of serum B vitamins on elevated plasma homocysteine levels associated with the mutation of methylenetetrahydrofolate reductase gene in Japanese. *Atherosclerosis*, **2002**, 164, 321-8	3.1	43
37	Molecular genetic analysis of familial hypercholesterolemia: spectrum and regional difference of LDL receptor gene mutations in Japanese population. *Atherosclerosis*, **2002**, 165, 335-42	3.1	57
36	Effects of hepatic lipase gene promoter nucleotide variations on serum HDL cholesterol concentration in the general Japanese population. *Journal of Human Genetics*, **2001**, 46, 172-7	4.3	27
35	An unsolved mystery of promoter variation in CETP gene and atherosclerosis. *European Journal of Clinical Investigation*, **2001**, 31, 558-9	4.6	1
34	Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. *Clinical Chemistry and Laboratory Medicine*, **2001**, 39, 380-4	5.9	116
33	Cholesteryl ester transfer protein and atherosclerosis. *Current Opinion in Lipidology*, **2000**, 11, 389-96	4.4	40
32	Effect of common methylenetetrahydrofolate reductase gene mutation on coronary artery disease in familial hypercholesterolemia. *American Journal of Cardiology*, **2000**, 86, 840-5	3	26
31	Additive effects of another kind of HMG-CoA reductase inhibitor with different pharmacokinetics in the treatment of heterozygous familial hypercholesterolemia. *Atherosclerosis*, **2000**, 153, 525-6	3.1	1
30	Common Mutation of 5, 10-Methylenetetrahydrofolate Reductase Accelerates Coronary Artery Disease in Familial Hypercholesterolemia **2000**, 62-64		
29	Abetalipoproteinemia caused by maternal isodisomy of chromosome 4q containing an intron 9 splice acceptor mutation in the microsomal triglyceride transfer protein gene. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1999**, 19, 1950-5	9.4	65
28	Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. *Atherosclerosis*, **1999**, 145, 405-13	3.1	21

27	Plasma homocysteine level and development of coronary artery disease. *Coronary Artery Disease*, **1999**, 10, 443-7	1.4	12
26	Effects of Combined Therapy Using Two Kinds of HMG-CoA Reductase Inhibitors in Heterozygous Familial Hypercholesterolemia. *The Journal of Japan Atherosclerosis Society*, **1999**, 27, 1-6		
25	Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia. *American Journal of Cardiology*, **1998**, 82, 113-7	3	28
24	Enzyme immunoassay for cholesteryl ester transfer protein in human serum. *Clinica Chimica Acta*, **1998**, 271, 109-18	6.2	33
23	A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. *Preventive Medicine*, **1998**, 27, 659-67	4.3	148
22	Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency. *Atherosclerosis*, **1997**, 132, 229-36	3.1	28
21	Cholesteryl ester transfer protein activity enhances plasma cholesteryl ester formation. Studies in CETP transgenic mice and human genetic CETP deficiency. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1997**, 17, 1045-52	9.4	42
20	A 4-year trial of simvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. *Current Therapeutic Research*, **1996**, 57, 62-71	2.4	
19	CETP(Cholesteryl Ester Transfer Protein) Deficiency Caused by Genetic Mutation in the CETP Gene in Normal Korean Population. *Sunhwangi*, **1996**, 26, 500		3
18	Molecular Genetics of Cholesterol Transport and Cholesterol Reverse Transport Disorders, and Coronary Heart Disease. *Medical Science Symposia Series*, **1996**, 371-377		
17	Molecular genetics of cholesterol transport and cholesterol reverse transport disorders (familial hypercholesterolemia and CETP deficiency) and coronary heart disease. *Annals of the New York Academy of Sciences*, **1995**, 748, 333-41	6.5	3
16	Absence of familial defective apolipoprotein B-100 in Japanese patients with familial hypercholesterolaemia. *Lancet, The*, **1995**, 345, 1438	40	19
15	Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia. *American Journal of Cardiology*, **1995**, 76, 47A-50A	3	6
14	Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. *Journal of Clinical Investigation*, **1994**, 94, 1872-82	15.9	192
13	Reduction of lipoprotein(a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia. *Atherosclerosis*, **1993**, 100, 65-74	3.1	32
12	Rapid detection and prevalence of cholesteryl ester transfer protein deficiency caused by an intron 14 splicing defect in hyperalphalipoproteinemia. *Human Genetics*, **1993**, 91, 13-6	6.3	19
11	Enhanced cholesteryl ester transfer protein activities and abnormalities of high density lipoproteins in familial hypercholesterolemia. *Hormone and Metabolic Research*, **1992**, 24, 284-8	3.1	45
10	Alternative splicing of the mRNA encoding the human cholesteryl ester transfer protein. *Biochemistry*, **1992**, 31, 2352-8	3.2	56

9	Compound heterozygote of cholesteryl-ester transfer protein deficiency in a patient with hyperalphalipoproteinemia. *Atherosclerosis*, **1992**, 96, 83-5	3.1	4
8	Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency. *Atherosclerosis*, **1991**, 90, 189-96	3.1	84
7	Novel gene mutations at the low density lipoprotein receptor locus: FH-Kanazawa and FH-Okayama. *Journal of Internal Medicine*, **1990**, 227, 247-51	10.8	8
6	Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. *New England Journal of Medicine*, **1990**, 323, 1234-8	59.2	722
5	Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. *Nature*, **1989**, 342, 448-51	50.4	426
4	Effects of LDL-Apheresis on Coronary Artery Stenosis in Patients with Familial Hypercholesterolemia. *The Journal of Japan Atherosclerosis Society*, **1989**, 17, 717-724		
3	Removal of apolipoprotein E-enriched high density lipoprotein by LDL-apheresis in familial hypercholesterolaemia: a possible activation of the reverse cholesterol transport system. *Atherosclerosis*, **1988**, 74, 1-8	3.1	13
2	The Effects of LDL-Apheresis and Plasma Exchange on Cholesterol Level and Lipid Composition of Low and High Density Lipoproteins in Homozygous Patients with Familial Hyper-Cholesterolemia. *The Journal of Japan Atherosclerosis Society*, **1988**, 16, 53-57		
1	Apolipoprotein A-I Gene Polymorphism in Patients with Coronary Heart Disease and Normolipidemic Controls. *The Journal of Japan Atherosclerosis Society*, **1987**, 15, 1521-1525		